467 related articles for article (PubMed ID: 7905786)
61. [Gene amplification in murine leukemia cells with multiple drug resistance acquired in vivo].
Demidova NS; Goncharova SA; Chernova OB; Kopnin BP; Gudkov AV
Genetika; 1987 Oct; 23(10):1797-806. PubMed ID: 3692152
[TBL] [Abstract][Full Text] [Related]
62. Increased survival after treatments with anticancer agents of Chinese hamster cells expressing the human Mr 27,000 heat shock protein.
Huot J; Roy G; Lambert H; Chrétien P; Landry J
Cancer Res; 1991 Oct; 51(19):5245-52. PubMed ID: 1913647
[TBL] [Abstract][Full Text] [Related]
63. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression.
Harker WG; Slade DL; Dalton WS; Meltzer PS; Trent JM
Cancer Res; 1989 Aug; 49(16):4542-9. PubMed ID: 2568172
[TBL] [Abstract][Full Text] [Related]
64. Multidrug resistance: a transport system of antitumor agents and xenobiotics.
Tsuruo T
Princess Takamatsu Symp; 1990; 21():241-51. PubMed ID: 1983721
[TBL] [Abstract][Full Text] [Related]
65. Effect of Calphostin C (PKC inhibitor) on daunorubicin resistance in P388/ADR and HL60/AR cells: reversal of drug resistance possibly via P-glycoprotein.
Gupta S; Patel K; Singh H; Gollapudi S
Cancer Lett; 1994 Jan; 76(2-3):139-45. PubMed ID: 7511983
[TBL] [Abstract][Full Text] [Related]
66. Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenyl-pyrido [3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice.
Waud WR; Leopold WR; Elliott WL; Dykes DJ; Laster WR; Temple CG; Harrison SD; Griswold DP
Cancer Res; 1990 Jun; 50(11):3239-44. PubMed ID: 2334919
[TBL] [Abstract][Full Text] [Related]
67. Monoclonal antibody MRK16 reverses the multidrug resistance of multidrug-resistant transgenic mice.
Mickisch GH; Pai LH; Gottesman MM; Pastan I
Cancer Res; 1992 Aug; 52(16):4427-32. PubMed ID: 1353705
[TBL] [Abstract][Full Text] [Related]
68. Techniques to reverse or circumvent drug-resistance in vitro.
Kuwano M; Nakagawa M; Shiraishi N; Yamaguchi T; Kikuchi J; Akiyama S
Prog Clin Biol Res; 1986; 223():163-71. PubMed ID: 3809198
[TBL] [Abstract][Full Text] [Related]
69. Resistance to anthrapyrazoles and anthracyclines in multidrug-resistant P388 murine leukemia cells: reversal by calcium blockers and calmodulin antagonists.
Klohs WD; Steinkampf RW; Havlick MJ; Jackson RC
Cancer Res; 1986 Sep; 46(9):4352-6. PubMed ID: 3460695
[TBL] [Abstract][Full Text] [Related]
70. In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia.
Johnson RK; Chitnis MP; Embrey WM; Gregory EB
Cancer Treat Rep; 1978 Oct; 62(10):1535-47. PubMed ID: 709555
[TBL] [Abstract][Full Text] [Related]
71. Oxygen radical detoxification enzymes in doxorubicin-sensitive and -resistant P388 murine leukemia cells.
Ramu A; Cohen L; Glaubiger D
Cancer Res; 1984 May; 44(5):1976-80. PubMed ID: 6324993
[TBL] [Abstract][Full Text] [Related]
72. Cross-resistance of cultured murine leukemia vincristine-resistant P388 cells to vinblastine, vindesine, and bis (N-ethylidene vindesine) disulfide, disulfate.
Wilkoff LJ; Dulmadge EA
J Natl Cancer Inst; 1982 Jun; 68(6):1023-6. PubMed ID: 6953266
[TBL] [Abstract][Full Text] [Related]
73. Circumvention of drug resistance of P388/R cells by the combination of adriamycin and mitoxantrone with hyperthermia (42 degrees C).
Juvekar AS; Chitnis MP
Neoplasma; 1991; 38(2):207-11. PubMed ID: 2041579
[TBL] [Abstract][Full Text] [Related]
74. A non-P-glycoprotein-mediated mechanism of vincristine transport which is affected by resistance modifiers and present in chemosensitive cells.
Gruber A; Larsson R; Nygren P; Björkholm M; Peterson C
Leukemia; 1994 Jun; 8(6):985-9. PubMed ID: 7911547
[TBL] [Abstract][Full Text] [Related]
75. [In vitro evaluation of the chemosensitivity of an experimental murine leukemia rendered resistant in vivo to adriamycin].
Lepri E; Menconi E; Barzi AM
Boll Soc Ital Biol Sper; 1984 Jul; 60(7):1369-75. PubMed ID: 6477749
[TBL] [Abstract][Full Text] [Related]
76. Mechanisms of multidrug resistance in HL60 cells: evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug.
McGrath T; Center MS
Cancer Res; 1988 Jul; 48(14):3959-63. PubMed ID: 2898287
[TBL] [Abstract][Full Text] [Related]
77. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein.
Dalton WS; Durie BG; Alberts DS; Gerlach JH; Cress AE
Cancer Res; 1986 Oct; 46(10):5125-30. PubMed ID: 2875788
[TBL] [Abstract][Full Text] [Related]
78. Structure and function of P-glycoprotein in the normal liver and intestine.
Arias IM; Gatmaitan Z; Mazzanti R; Shu H; Kumamoto Y
Princess Takamatsu Symp; 1990; 21():229-39. PubMed ID: 1983720
[TBL] [Abstract][Full Text] [Related]
79. Time course of MDR gene amplification during in vivo selection for doxorubicin-resistance and during reversal in murine leukemia L 1210.
Volm M; Mattern J; Pommerenke EW
Anticancer Res; 1991; 11(2):579-85. PubMed ID: 1676579
[TBL] [Abstract][Full Text] [Related]
80. Modulation of drug resistance in a daunorubicin resistant subline with oligonucleoside methylphosphonates.
Vasanthakumar G; Ahmed NK
Cancer Commun; 1989; 1(4):225-32. PubMed ID: 2576974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
